Anzeige
Mehr »
Login
Samstag, 02.03.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
High-Grade News! Heute wieder ein 57% Kursspektakel?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EDH2 | ISIN: US8902608541 | Ticker-Symbol: TPM0
NASDAQ
01.03.24
21:54 Uhr
0,365 US-Dollar
-0,013
-3,46 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TONIX PHARMACEUTICALS HOLDING CORP Chart 1 Jahr
5-Tage-Chart
TONIX PHARMACEUTICALS HOLDING CORP 5-Tage-Chart

Aktuelle News zur TONIX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTonix Pharmaceuticals Holding Corp. - 8-K, Current Report3
MoTonix Pharmaceuticals: New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain2.493Bedtime drug being developed by Tonix relieved pain by targeting fibromyalgia's characteristic "non-restorative sleep": Potential for FDA Approval in 2025CHATHAM, NJ / ACCESSWIRE / February 26, 2024...
► Artikel lesen
20.02.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference1
15.02.Tonix reports promising fibromyalgia drug study results2
15.02.Tonix Pharmaceuticals: Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction367Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigueLatest Phase 3 trial achieved primary endpoint (p=0.00005)Potential for FDA Approval in 2025CHATHAM, NJ / ACCESSWIRE...
► Artikel lesen
14.02.Tonix signs on Rho to support NDA submission for fibromyalgia drug1
14.02.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya, Plans to File NDA for FDA Approval in Second Half of 20241
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 5711The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS87166L2097 SYNLOGIC...
► Artikel lesen
13.02.Tonix Pharmaceuticals plans FDA submission for fibromyalgia drug2
12.02.Tonix stock climbs 9% after FDA approves PTSD study2
12.02.Tonix Pharma rises on FDA nod to human trials for PTSD drug2
12.02.Tonix's PTSD drug cleared for phase 2 trauma trial2
12.02.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report1
09.02.Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Getting Patients Addicted In Phase 3 Trial1
01.02.Tonix Pharmaceuticals: New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval338Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005)Combination of broad-spectrum relief and favorable tolerability seen as distinguishing, competitive featuresCompany...
► Artikel lesen
31.01.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID138Retrospective observational study of electronic medical records of more than 90 million people living in the U.S. Long COVID shares symptoms with chronic overlapping pain disorders like fibromyalgia...
► Artikel lesen
30.01.New Hope For Fibromyalgia Patients? Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval1
29.01.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Trade Name for TNX-102 SL for the Management of Fibromyalgia130Results from two positive Phase 3 studies point to Tonmya's (TNX-102 SL) potential as a new first-line medicine for chronic use in managing fibromyalgia, a debilitating condition suffered by 6-12...
► Artikel lesen
29.01.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report1
25.01.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.2
Seite:  Weiter >>
108 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1